全文获取类型
收费全文 | 42999篇 |
免费 | 2957篇 |
国内免费 | 133篇 |
专业分类
耳鼻咽喉 | 407篇 |
儿科学 | 1383篇 |
妇产科学 | 1134篇 |
基础医学 | 5888篇 |
口腔科学 | 809篇 |
临床医学 | 6657篇 |
内科学 | 8136篇 |
皮肤病学 | 735篇 |
神经病学 | 4129篇 |
特种医学 | 786篇 |
外国民族医学 | 2篇 |
外科学 | 4104篇 |
综合类 | 471篇 |
一般理论 | 56篇 |
预防医学 | 5136篇 |
眼科学 | 597篇 |
药学 | 2486篇 |
中国医学 | 81篇 |
肿瘤学 | 3092篇 |
出版年
2023年 | 215篇 |
2022年 | 388篇 |
2021年 | 964篇 |
2020年 | 540篇 |
2019年 | 1017篇 |
2018年 | 1156篇 |
2017年 | 806篇 |
2016年 | 822篇 |
2015年 | 1038篇 |
2014年 | 1408篇 |
2013年 | 2111篇 |
2012年 | 3045篇 |
2011年 | 3177篇 |
2010年 | 1776篇 |
2009年 | 1491篇 |
2008年 | 2857篇 |
2007年 | 2889篇 |
2006年 | 2897篇 |
2005年 | 2688篇 |
2004年 | 2547篇 |
2003年 | 2425篇 |
2002年 | 2296篇 |
2001年 | 393篇 |
2000年 | 350篇 |
1999年 | 472篇 |
1998年 | 477篇 |
1997年 | 436篇 |
1996年 | 381篇 |
1995年 | 333篇 |
1994年 | 320篇 |
1993年 | 293篇 |
1992年 | 307篇 |
1991年 | 292篇 |
1990年 | 261篇 |
1989年 | 259篇 |
1988年 | 225篇 |
1987年 | 211篇 |
1986年 | 201篇 |
1985年 | 181篇 |
1984年 | 222篇 |
1983年 | 211篇 |
1982年 | 217篇 |
1981年 | 194篇 |
1980年 | 184篇 |
1979年 | 143篇 |
1978年 | 96篇 |
1977年 | 109篇 |
1976年 | 89篇 |
1974年 | 91篇 |
1973年 | 84篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
Emeline Colomba Patricia Pautier Fanny Pommeret Alexandra Leary 《Expert review of anticancer therapy》2019,19(6):437-446
Introduction: The landscape of poly (ADP-ribose) polymerase (PARP) inhibition in ovarian cancer is rapidly evolving and becoming increasingly complex. Ovarian cancer is leading therapeutic innovation by providing the proof of concept for DNA repair as a target. Three different PARP inhibitors have now received approvals in the US and Europe in different indications. Subtle but crucial differences can be found among the licensed indications for each PARP inhibitor in terms of histology, type of BRCA mutation (germline and/or somatic), number of prior lines of chemotherapy and whether the indication is in the treatment or maintenance settings.
Areas covered: We review the latest clinical data regarding the PARP inhibitor rucaparib in ovarian cancer, provide an update on the evolving landscape of PARP inhibition in ovarian cancer, and summarize avenues of ongoing and future research.
Expert opinion: All eligible patients should be offered a PARP inhibitor. SOLO1 trial results demonstrated an unprecedented benefit maintenance with PARP inhibitors in first line. Results from trials evaluating PARP inhibitors as maintenance in first line regardless of BRCA status and from trials evaluating combinatorial strategies are eagerly awaited. 相似文献
3.
4.
Nurse perceptions of the Nursing Delirium Screening Scale in two palliative care inpatient units: a focus group study 下载免费PDF全文
5.
Ana Lopez Alonso 《Platelets》2015,26(4):317-323
AbstractWhile the interactions between Gram-positive bacteria and platelets have been well characterized, there is a paucity of data on the interaction between other pathogens and platelets. However, thrombocytopenia is a common feature with many infections especially viral hemorrhagic fever. The little available data on these interactions indicate a similarity with bacteria-platelet interactions with receptors such as FcγRIIa and Toll-Like Receptors (TLR) playing key roles with many pathogens. This review summarizes the known interactions between platelets and pathogens such as viruses, fungi and parasites. 相似文献
6.
Maria Gonzalez-Cao Cristina Carrera Juan Francisco Rodriguez Moreno Pedro Rodríguez-Jiménez Mónica Antoñanzas Basa Rosa Feltes Ochoa Teresa Puertolas Eva Muñoz-Couselo José Luis Manzano Ivan Marquez-Rodas Juan Martín-Liberal Ainara Soria Pilar Lopez Criado Almudena Garcia-Castaño Aram Boada Pablo Ayala de Miguel Susana Puig Guillermo Crespo Alfonso Berrocal 《Journal of the American Academy of Dermatology》2021,84(5):1412-1415
7.
8.
Luis Veloza Cristina Teixido Natalia Castrejon Fina Climent Ana Carri Marta Marginet Davide Soldini Blanca Gonzlez‐Farr Inmaculada Ribera‐Cortada Armando Lopez‐Guillermo Eva Gonzlez‐Barca Adriana Sierra Mileyka Herrera Cndida Gmez Adriana Garcia Olga Balagu Elias Campo Antonio Martinez 《Histopathology》2019,75(6):799-812
9.
Pedro Lopez Matheus Daros Pinto Ronei Silveira Pinto 《Ultrasound in medicine & biology》2019,45(2):612-616
In the work described here, our aim was to determine, in an elderly population, changes in muscle thickness (MT), cross-sectional area (CSA) and echo intensity (EI) of the quadriceps muscles at four time points (0, 5, 10 and 15 min; i.e., T0, T5, T10 and T15, respectively) after changing from a standing to supine position. Twenty-one elderly participants (14 men: 68.1 ± 4.6 y; 8 women: 66.8 ± 4.1 y) were evaluated at four time points. Rectus femoris CSA (RFCSA), MT and EI of the quadriceps femoris (QF) muscles were assessed. EI significantly increased from T0 to T5, T10 and T15 (p < 0.001), whereas no differences were observed between T5 and T15 in the rectus femoris (RFEI), vastus intermedius (VIEI) and quadriceps femoris (QFEI). No differences were observed between any time points in the RFCSA and MT of QF muscles. In summary, these results suggest that periods >5 min are not necessary to obtain consistent MT and EI measurements of quadriceps femoris muscles in the elderly population. 相似文献
10.